Renin-Angiotensin System Inhibitors and COVID-19: Potential Therapeutics Rather Than Perpetrators.
作者信息
Wang Tzung-Dau
机构信息
Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
出版信息
Acta Cardiol Sin. 2020 May;36(3):179-182. doi: 10.6515/ACS.202005_36(3).20200430A.
Abstract
摘要
相似文献
1
Renin-Angiotensin System Inhibitors and COVID-19: Potential Therapeutics Rather Than Perpetrators.肾素-血管紧张素系统抑制剂与2019冠状病毒病：潜在的治疗手段而非致病因素。
Acta Cardiol Sin. 2020 May;36(3):179-182. doi: 10.6515/ACS.202005_36(3).20200430A.
2
Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.COVID-19 患者住院期间继续或停用肾素-血管紧张素系统抑制剂：一项前瞻性、随机、开放标签试验。
Lancet Respir Med. 2021 Mar;9(3):275-284. doi: 10.1016/S2213-2600(20)30558-0. Epub 2021 Jan 7.
3
Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: A new challenge overcome?关于肾素-血管紧张素系统抑制剂在新冠病毒后期研究中作用的系统综述：新的挑战是否已被克服？
Int J Cardiol. 2020 Dec 15;321:150-154. doi: 10.1016/j.ijcard.2020.07.041. Epub 2020 Jul 30.
4
[Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers].[年龄、合并症及肾素-血管紧张素-醛固酮系统在新型冠状病毒肺炎中的作用。血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂的影响]
Kardiologiia. 2020 Apr 8;60(4):4-9. doi: 10.18087/cardio.2020.4.n1122.
5
Impact of renin-angiotensin-aldosterone system inhibitors on COVID-19.肾素-血管紧张素-醛固酮系统抑制剂对 COVID-19 的影响。
Hypertens Res. 2022 Jul;45(7):1147-1153. doi: 10.1038/s41440-022-00922-3. Epub 2022 May 18.
6
COVID-19: Acing the Treatment.COVID-19：治疗大获成功。
Med Princ Pract. 2023;32(1):86-89. doi: 10.1159/000525550. Epub 2022 Aug 15.
7
Renin-Angiotensin System Pathway Therapeutics Associated With Improved Outcomes in Males Hospitalized With COVID-19.肾素-血管紧张素系统通路治疗与 COVID-19 住院男性患者的改善结局相关。
Crit Care Med. 2022 Sep 1;50(9):1306-1317. doi: 10.1097/CCM.0000000000005589. Epub 2022 May 18.
8
What solid organ transplant healthcare providers should know about renin-angiotensin-aldosterone system inhibitors and COVID-19.实体器官移植医护人员应该了解的肾素-血管紧张素-醛固酮系统抑制剂与 COVID-19 相关知识。
Clin Transplant. 2020 Jul;34(7):e13991. doi: 10.1111/ctr.13991. Epub 2020 Jun 15.
9
Renin-Angiotensin-Aldosterone Inhibitors and COVID-19 Infection.肾素-血管紧张素-醛固酮抑制剂与 COVID-19 感染。
Curr Hypertens Rep. 2022 Oct;24(10):425-433. doi: 10.1007/s11906-022-01207-3. Epub 2022 Jun 18.
10
Chronic use of renin-angiotensin-aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis.慢性使用肾素-血管紧张素-醛固酮抑制剂治疗高血压合并 COVID-19 患者：来自西班牙登记和荟萃分析的结果。
Med Clin (Barc). 2022 Apr 8;158(7):315-323. doi: 10.1016/j.medcli.2021.04.005. Epub 2021 May 6.
引用本文的文献
1
Repurposing of existing FDA approved drugs for Neprilysin inhibition: An study.将现有美国食品药品监督管理局（FDA）批准的药物用于抑制中性肽链内切酶：一项研究。
J Mol Struct. 2021 Jan 15;1224:129073. doi: 10.1016/j.molstruc.2020.129073. Epub 2020 Aug 12.
2
The Crucial Importance of Optimal Primary and Secondary Prevention of Cardiovascular Disease during COVID-19 Pandemic.新冠疫情期间心血管疾病一级和二级预防优化的至关重要性
Acta Cardiol Sin. 2020 Jul;36(4):396. doi: 10.6515/ACS.202007_36(4).20200619B.
本文引用的文献
1
Impact of Apelin-13 on the Development of Coronary Artery Ectasia.Apelin-13对冠状动脉扩张发展的影响。
Acta Cardiol Sin. 2020 May;36(3):216-222. doi: 10.6515/ACS.202005_36(3).20190901A.
2
Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.中国武汉因 2019 年冠状病毒病（COVID-19）感染而住院的高血压患者中，肾素-血管紧张素系统抑制剂与严重程度或死亡风险的关系。
JAMA Cardiol. 2020 Jul 1;5(7):825-830. doi: 10.1001/jamacardio.2020.1624.
3
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.住院 COVID-19 合并高血压患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的住院使用率与死亡率的关系。
Circ Res. 2020 Jun 5;126(12):1671-1681. doi: 10.1161/CIRCRESAHA.120.317134. Epub 2020 Apr 17.
4
Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2.血管紧张素转换酶 2：SARS-CoV-2 受体和肾素-血管紧张素系统的调节剂：庆祝 ACE2 发现 20 周年。
Circ Res. 2020 May 8;126(10):1456-1474. doi: 10.1161/CIRCRESAHA.120.317015. Epub 2020 Apr 8.
5
Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.肾素-血管紧张素系统阻滞剂与 COVID-19 大流行：目前尚无证据表明应放弃使用肾素-血管紧张素系统阻滞剂。
Hypertension. 2020 Jun;75(6):1382-1385. doi: 10.1161/HYPERTENSIONAHA.120.15082. Epub 2020 Mar 25.
6
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?高血压和糖尿病患者感染新型冠状病毒肺炎（COVID-19）的风险会增加吗？
Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.
7
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
8
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
9
Effects of Levosimendan on Right Ventricular Function in Patients with Acute Decompensated Heart Failure.左西孟旦对急性失代偿性心力衰竭患者右心室功能的影响
Acta Cardiol Sin. 2019 Nov;35(6):585-591. doi: 10.6515/ACS.201911_35(6).20190327A.
10
Targeted Next Generation Sequencing for Genetic Mutations of Dilated Cardiomyopathy.扩张型心肌病基因突变的靶向新一代测序
Acta Cardiol Sin. 2019 Nov;35(6):571-584. doi: 10.6515/ACS.201911_35(6).20190402A.
Zotero 插件